HIV pharmaceutical market leader Gilead reports 13% sales increase

Sept. 10, 2011 - PRLog -- The report ‘The HIV Market Outlook to 2016’ provides in-depth coverage of the HIV market, including a detailed epidemiological analysis. The report researches top brands, and profiles leading players in the HIV market.

The US dominated sales in the global HIV market, accounting for over 50% of sales in 2010. Jointly, the leading pharmaceutical markets of the EU were the second largest HIV market with a market share of just over 33%. Countries with the highest endemicity of HIV actually only account for very small market shares.

The current market for HIV treatment is dominated by once-daily regimens. There is a strong trend towards regimen simplification and reduced pill burden, which has resulted in the fast penetration of several once daily treatment options. To this end Gilead is developing a Quad Pill which contains four active ingredients the first such product. Gilead was the leading company in the 2010 recording sales of over $6bn at a Y-o-Y growth of over 13%.

Read more here: http://www.pharmaceutical-market-research.com/publication...

Pharmaceutical-market-research.com is the source for information products concerning the global biotechnology, healthcare, medical device and pharmaceutical industries. With over 26,000 market reports available, executives can find a current and comprehensive range of specialised intelligence. www.pharmaceutical-market-research.com is a service from Piribo Ltd, which was founded in 2004.

# # #

About Piribo.
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.